Back to Results
First PageMeta Content
Pfizer / Gabapentin / Off-label use / Valdecoxib / Prescription medication / Pharmaceutical industry / Medical prescription / Side effect / Olanzapine / Pharmacology / Pharmaceutical sciences / Clinical research


Document Date: 2012-04-09 16:49:25

Open Document

File Size: 262,42 KB

Share Result on Facebook

City

Cincinnati / Boston / New York / Washington / D.C. / /

Company

Eli Lilly / All Inc. / Warner-Lambert Co. LLC / IMS HEALTH INC. ET / PREVENTING WIDESPREAD ILLEGAL OFFLABEL PROMOTION / Pfizer / Prescription Access Litigation LLC / Inspector General / CURIAE1 Community Catalyst Inc. / The Kaiser Family Fund. / Verispan / SDI / /

Country

United States / /

Currency

USD / /

/

Event

M&A / /

Facility

Supreme Court / /

IndustryTerm

illegal off-label promotional communications / /

Organization

Off-label Prescribing Among Office / Kaiser Family Fund / Supreme Court / United States Court of Appeals / School of Law / Drug and Device Promotion / office of the Inspector General / AMICI CURIAE AFSCME DISTRICT COUNCIL / Seton Hall Univ. / U.S. Attorney's Office / FDA / AFSCME District Council / Center for Health and Pharmaceutical Law / /

Person

Wells G. Wilkinson / G. Caleb Alexander / Sector Payors / David C. Radley / David Evans / Jim Edwards / /

/

Position

Counsel / Georgia John Maheras Counsel / Record Counsel / contractor / Counsel for Amicus AFSCME Dist / United States Attorney / /

Product

Bextra / Off-Label Drug / Warner-Lambert Acquisition Has Side Effects / /

ProgrammingLanguage

DC / /

ProvinceOrState

AFSCME DISTRICT / New York / District of Columbia / Massachusetts / /

PublishedMedium

USA Today / /

Technology

html / pdf / /

URL

http /

SocialTag